AstraZeneca Takes A Fancy To Peregrine's Bavituximab In IO Combo
This article was originally published in Scrip
Executive Summary
AstraZeneca PLC has forged what is the latest in a string of clinical collaborations involving its anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI-4736), announcing Aug. 24 a deal to evaluate the compound in combination with US biotech Peregrine Pharmaceuticals Inc.'s first-in-class agent bavituximab.